Skip to main content

Decipher Biosciences, Inc. (DECI)

Decipher Biosciences will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Market Capn/a
Revenue (ttm)33.26M
Net Income (ttm)-5.83M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Price Targetn/a
Est. Earnings Daten/a

About DECI

Decipher Biosciences is a commercial-stage precision oncology company committed to improving patient care, with a focus in urologic oncology specific to prostate and bladder cancers. Our novel prostate cancer genomic testing products, Decipher Biopsy and Decipher RP, provide valuable information about the underlying biology of a patient’s tumor, assisting physicians in their selection of an optimal therapy. Our differentiated approach measures the biological activity of a patient’s entire tumor genome, known as whole transcriptome analysis,...

IndustryMedical Devices
IPO DatePending
CEOTina S. Nova, Ph.D.
Stock ExchangeNASDAQ
Ticker SymbolDECI
Full Company Profile

Financial Performance

In 2019, DECI's revenue was $16.52 million, an increase of 36.89% compared to the previous year's $12.07 million. Losses were -$18.45 million, -38.37% less than in 2018.

Financial Statements


Genomics testing provider Decipher Biosciences files for a $100 million IPO

Decipher Biosciences, which provides genomic testing products for urologic oncology, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.

8 months ago - NASDAQ

Decipher Biosciences IPO Registration Document (S-1)

Decipher Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.

8 months ago - SEC